Compare CMPR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPR | NVCR |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | Ireland | Switzerland |
| Employees | N/A | N/A |
| Industry | Publishing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2005 | 2015 |
| Metric | CMPR | NVCR |
|---|---|---|
| Price | $84.40 | $15.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $86.50 | $28.08 |
| AVG Volume (30 Days) | 167.8K | ★ 1.1M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 553.45 | 21.79 |
| EPS | ★ 3.79 | N/A |
| Revenue | ★ $3,736,643,000.00 | $655,353,000.00 |
| Revenue This Year | $10.43 | $7.72 |
| Revenue Next Year | $5.46 | $6.74 |
| P/E Ratio | $22.51 | ★ N/A |
| Revenue Growth | ★ 9.80 | 8.28 |
| 52 Week Low | $56.34 | $9.82 |
| 52 Week High | $106.58 | $21.45 |
| Indicator | CMPR | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 33.98 | 37.66 |
| Support Level | $80.73 | $14.84 |
| Resistance Level | $105.61 | $18.43 |
| Average True Range (ATR) | 3.03 | 0.80 |
| MACD | -0.26 | -0.27 |
| Stochastic Oscillator | 4.91 | 8.31 |
Cimpress PLC helps millions of businesses build brands, stand out, and grow via customized physical marketing products and branded merchandise. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. It has five segments VistaPrint, PrintBrothers, The Print Group, National Pen, and All Other Businesses. Majority of revenue comes from VistaPrint segment which provides graphic design services, VistaCreate for do-it-yourself (DIY) design, etc. It has presence in North America, Europe, and Other. The company generates majority of revenue is from Europe.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.